Golcadomide (GOLCA; CC-99282), a Potential First-in-Class Oral CELMoD™ Agent, with R-CHOP, As First-Line (1L) Therapy in Aggressive B-Cell Lymphoma (A-Bcl): Safety and Efficacy in an Open-Label, Multicenter, Phase 1b Trial
Clinical Lymphoma Myeloma and Leukemia（2024）
关键词
ABCL,first-in-class,lymphoma,targeted protein degradation,combination therapy,phase 1
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要